Geron (NASDAQ:GERN) focuses on the development and commercialization of therapeutics for oncology and other age-related diseases. Its most well-known project involves the development of its flagship drug, imetelstat, a novel telomerase inhibitor aimed at treating myeloid malignancies. The company's objective is to advance imetelstat through clinical trials, aiming for its commercialization as a treatment option for patients with hematologic malignancies. Geron's operations are chiefly concentrated on research and development activities, with a strong emphasis on innovation and collaboration with leaders in the field of oncology to potentially improve patient outcomes.